Navigation Links
Early Bird Discounts Available on International Healthcare and Biotechnology Conferences, Save Up To $600 with Global Information
Date:5/22/2012

FARMINGTON, Conn., May 22, 2012 /PRNewswire-iReach/ -- Global Information Inc is pleased to announce limited available early bird discounted registration for three significant international healthcare conferences:

2nd Annual World Health Care Congress – Latin America

October 29-30, 2012 - Sao Paulo, Brazil – The 2nd Annual World Health Care Congress – Latin America builds on a successful inaugural event and features best practices and innovations to deliver quality, cost-effective health care.

The first Annual World Health Care Congress-Latin America  convened health care's most senior international executives and government officials to share business cases, best-practices and actionable solutions to foster innovations that improve quality, cost and accountability.  The 2011 Congress featured the top industry influencers including Hans Dohmann, MD Municipal Secretary for Health, Brazil; Dr Pedro Garcia Aspillaga, Former Minister of Health of Chile; Sergio Cortes, State Secretary of Health, Brazil; Leandro Reis, Deputy Chairman, National Health Agency (ANS); Marcio Seroa de Araujo Coriolano, President; Bradesco Saude S/A, President;  FENASAUDE, Jose Seripieri, Chairman of Qualicorp; and many others.

Register for this conference before 2012/07/20 and receive a $600 early bird discount at http://www.giiconference.com/woco224416-2012/

Bio-IT World Expo Europe 2012

October 9-11, 2012 - Vienna, Austria - The Fourth Annual Bio-IT World Europe Conference & Expo attracts life sciences, pharmaceutical, informatics and IT professionals from across Europe and the rest of the world. This year's conference will feature
'/>"/>

SOURCE Global Information, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology news :

1. Clinical trials for Alzheimers disease preventative drug to begin early 2013
2. Nearly one-tenth of hemispheres mammals unlikely to outrun climate change
3. Begin early: Researchers say water with meals may encourage wiser choices
4. Study: Men who do load-bearing exercise in early 20s may be shielded from osteoporosis
5. Attendees Save Up To $800 on Boston-area Pharmaceutical and Healthcare Conferences, Early Bird Discounts Expiring April 27
6. New study links air pollution and early death in the UK
7. Early detection techniques offer hope for improved outcomes in lung cancer patients
8. Promising developments in early diagnosis and treatment of mesothelioma
9. A new gene thought to be the cause in early-onset forms of Alzheimers disease
10. Early warning system for seizures could cut false alarms
11. American Society of Plant Biologists honors early career women scientists
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... HUNTSVILLE, Ala. , March 2, 2015 /PRNewswire/ ... transaction processing. Data protection company Tharon Rankins Enterprises ... product that provides an ultra-safe way for businesses ... as their financial transactions. Beconux ... by Tharon Rankins Enterprises. Functioning similarly to an ...
(Date:2/24/2015)... This report analyzes the worldwide markets for Iris ... for the US, Canada , ... Asia-Pacific , Middle East , and ... are provided for the period 2013 through 2020. Also, a ... and analytics are derived from primary and secondary research. Company ...
(Date:2/23/2015)... , Feb. 23, 2015 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... provisional patent 62114357 for DISTRIBUTED VOICE DIRECTED ... NXT-ID introduces a new groundbreaking payment method. Payment accounts ... account may only be accessed if both the speech ...
Breaking Biology News(10 mins):Personal Data Protection Company Launches New Product 2World Iris Biometrics Industry 2World Iris Biometrics Industry 3World Iris Biometrics Industry 4World Iris Biometrics Industry 5World Iris Biometrics Industry 6World Iris Biometrics Industry 7World Iris Biometrics Industry 8World Iris Biometrics Industry 9World Iris Biometrics Industry 10World Iris Biometrics Industry 11NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3
... 2013 Disulfiram was the first medication approved for ... works, at least in part, by preventing the metabolism ... in the body quickly cause unpleasant symptoms, including nausea, ... a very strong incentive to avoid drinking. ...
... the fate of the original Otom inhabitants of Xaltocan, ... unknown. Researchers have long wondered whether they assimilated with ... to new anthropological research from The University of Texas ... the answers may lie in DNA. Following this line ...
... Thailand and Morocco have found that DHEA-S may prevent ... patients. In a report appearing in the February 2013 ... they describe how a network of steroid molecules found ... infection leading to brain damage. This suggests that treatment ...
Cached Biology News:Disulfiram: New support for an old addiction drug 2Aztec conquest altered genetics among early Mexico inhabitants, new DNA study shows 2A 'neurosteroid' found to prevent brain injury caused by HIV/AIDS 2
(Date:3/3/2015)... /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today ... odour control projects in North America , the ... . "Bidding activity in 2015 continues to be robust" ... high volume year for bidding in 2014, we are pleased to ... orders reflect the organization,s renewed focus on select market segments where ...
(Date:3/3/2015)... , March 3, 2015 Adaptive Biotechnologies ... CFO, is joining its Board of Director as Chair ... officer at Zillow Group, Chad oversees all finance, treasury ... built the company,s core finance, treasury and accounting functions, ... and nine acquisitions. In 2013, he was named Puget ...
(Date:3/3/2015)... March 3, 2015 Fried, Frank, Harris, Shriver ... Lewis has joined the Firm as a partner ... New York office. Mr. Lewis ... as well as other intellectual property and general litigation. ... Lewis represents both plaintiffs and defendants in a range ...
(Date:3/3/2015)... , March 3, 2015  Thingee Corporation, a software ... delivering a presentation entitled, "Technology Adoption: Making Reps, Lives ... through Innovations and Technology ,  in Deerfield ... to 13, 2015. Audiences looking to learn how technology ... want to be in the audience for the Thingee ...
Breaking Biology Technology:Adaptive Biotechnologies adds Chad Cohen, Zillow Group CFO, to Board of Directors 2Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 2Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 3Thingee to present at 11th Annual Synergistix Users Conference 2
... Sept. 8 Don Margolis, Chairman of,The Repair ... based in,Bangkok, Thailand told The Wall Street Transcript ... future profits inside the stem cell,research sector will ... five years, even for,companies specializing in Repair Stem ...
... 7th International ... Symposium on Uveitis in Germany, ZURICH, Switzerland, Sept. ... today announced that the,company has successfully completed its Phase I ... indications. In,April 2008, ESBATech initiated the Phase I study designed ...
... RNA levels, following 4 weeks of treatment with R7128 1500mg BID with Pegasys(R) plus ... Copegus(R) -, ... ... 8 Pharmasset, Inc.,(Nasdaq: VRUS ) announces the preliminary results of the fourth cohort ...
Cached Biology Technology:Stem Cell Profits Five Years Away, Says Repair Stem Cell Institute Chairman to The Wall Street Transcript 2ESBATech Announces Successful Completion of Phase I Clinical Study for Lead Antibody Fragment in Ophthalmic Indications 2Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 2Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 3Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 4Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 5Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 6